-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Regeneron and Sanofi jointly announced that the U.
Eosinophilic esophagitis is a chronic, progressive type 2 inflammatory disease that damages the esophagus, preventing it from working properly
Dupixent is a fully humanized monoclonal antibody that inhibits the signaling of IL-4 and IL-13 proteins
▲ The mechanism of action of Dupixent (Image source: Sanofi official website)
This sBLA is supported by two Phase 3 clinical trials, as well as data from a long-term extension trial
The companies plan to file regulatory applications around the world in 2022 to expand the use of Dupixent
References:
[1] FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis.